Announcement PDF Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026 MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 7 May 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations related to the Company’s development program in Multiple System Atrophy (MSA) will be delivered at multiple medical conferences in May 2026. The International Society for Magnetic Resonance in Medicine 2026 ISMRM and ISMRT Annual Meeting and Exhibition • Title: Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA (Abstract #03335) • Type: Oral Presentation • Presenter: Paula Trujillo, PhD, Research Assistant Professor, Department of Neurology, Vanderbilt University Medical Center • Date/Time: Tuesday, May 12, 2026, 16:00-17:50 local time • Location: Cape Town, South Africa Movement Disorder Society of Australia and New Zealand (MDSANZ) Scientific Meeting • Title: Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate • Type: Poster Presentation • Presenter: Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity • Conference Dates: May 15-17, 2026 • Location: Sydney, Australia MSA Symposium 2026 • Title: ATH434 Clinical Update and Phase 3 Planning • Type: Oral Presentation • Presenter: David Stamler, M.D., CEO of Alterity Therapeutics • Date/Time: Monday, May 18, 2026, 16.15-17.00 local time • Location: London, UK About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com. Authorisation & Additional information This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Contacts: Investors: Elyse Shapiro ir@alteritytx.com Remy Bernarda Investor Relations Advisory Solutions ir@alteritytx.com +1 (415) 203-6386 Media Casey McDonald Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com +1 (646) 577-8520 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.